When a drug is administered intravenously, it's a direct deposit into the bloodstream. 100% of the dose is available to the body. But when a drug is taken orally, it faces a long and perilous journey. The fraction of that oral dose that successfully reaches systemic circulation, unchanged, is called its bioavailability, denoted by the letter F.

We measure this by tracking the drug's concentration in the blood plasma over time. By plotting concentration versus time, we can calculate the total drug exposure, known as the Area Under the Curve or AUC. To find the absolute bioavailability of an oral drug, we compare its AUC to the AUC of the same dose given intravenously.

Why isn't bioavailability for an oral drug always 100%? The primary reason is the first-pass effect. After a drug is absorbed from the gastrointestinal (GI) tract, the blood that carries it flows directly to the liver via the portal vein before reaching the rest of the body. The cells of the intestinal wall and the liver are packed with enzymes, particularly the cytochrome P450 family, which can metabolize—or chemically alter—the drug before it ever has a chance to exert its effect.

If a drug is poorly absorbed from the intestine ($f_a$ is low) or heavily metabolized by the liver ($f_h$ is low), its oral bioavailability will be poor, and a much larger oral dose might be needed compared to an IV dose to achieve the same effect.

Bioavailability tells us how much drug gets in, but the absorption rate constant, $k_a$, tells us how fast. A larger $k_a$ means the drug is absorbed more quickly. This rate directly influences two other critical parameters: $T_{max}$, the time it takes to reach the highest concentration, and $C_{max}$, the peak concentration itself.

A faster absorption rate (higher $k_a$) leads to a shorter $T_{max}$ and a higher $C_{max}$. Conversely, a slower absorption (lower $k_a$) results in a longer, flatter concentration curve—it takes more time to reach a lower peak. This trade-off is crucial. For a painkiller, a fast onset (short $T_{max}$) is desirable. For a drug treating a chronic condition, a slower, more sustained release might be better to minimize side effects associated with high peak concentrations.

For a drug to be absorbed, it must cross the lipid membranes of the cells lining the GI tract. Its ability to do so depends heavily on its chemical properties, specifically whether it is ionized (charged) or non-ionized (neutral). Only the non-ionized form is lipid-soluble enough to diffuse passively across the membrane.

The fraction of a drug that is in its non-ionized state is determined by its pKa (the pH at which it is 50% ionized) and the pH of its environment. This relationship is described by the Henderson-Hasselbalch equation an essential tool for predicting where in the GI tract a drug will be best absorbed. For example, a weak acid will be mostly non-ionized in the acidic environment of the stomach, while a weak base will be better absorbed in the more alkaline environment of the small intestine.

However, absorption isn't just about passive diffusion. The gut wall is equipped with numerous transporter proteins that can actively pull drugs into cells or pump them back out. When a drug's absorption relies on these transporters, it no longer follows simple first-order kinetics. Instead, it can become saturated, a process described by Michaelis-Menten kinetics. At high drug concentrations, the transporters can become fully occupied, making the rate of absorption constant and independent of how much more drug is administered. This can create a bottleneck, limiting the Cmax and affecting overall bioavailability.

Understanding these quantitative relationships is the core of pharmacokinetics, allowing us to predict how a drug will behave in the body and design dosing regimens that are both safe and effective.